ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
Issued March 16, 2018
Issue
Cases of immune-mediated encephalitis and meningoencephalitis, some with fatal outcomes, have been reported in patients treated with ZINBRYTA. No cases have been reported in Canada.
Hazard description
Product safety
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker